Celltech float boost for B&C administrators
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE administrators of British & Commonwealth, the collapsed financial services group, could realise nearly pounds 60m next month when Celltech, the biotechnology company, is expected to come to the stock market, writes Paul Durman.
British & Commonwealth has a 36 per cent stake in Celltech, which is seeking treatments for septic shock and cancer. Celltech's shares, already traded under the Stock Exchange's matched bargain rule, have recently changed hands at about 550p, valuing the company at pounds 160m. Other large shareholders, besides B&C, will be offered the chance to sell some of their holdings.
Peter Allen, finance director, said the share price had jumped from 400p in July following Celltech's recent deals with Hoffman-La Roche and Bayer.
Celltech intends to issue new shares, raising more than pounds 30m to fund its drug research. It is believed this will give the company ready funds of about pounds 50m.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments